NovaBridge Biosciences
VIS-101
wet age-related macular degeneration (wet AMD)
Resolved
120days ago
Phase 2 readout · Mar 9, 2026
What's at stake
Phase 2 trial results for VIS-101 in wet age-related macular degeneration (wet AMD) are due Mar 9, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“VIS-101 KOL Perspective VIS-101 Next Steps Q&A Today’s Agenda 2 Today’s Speakers Emmett T. Cunningham, Jr., MD, PhD, MPH Executive Chairman, Co-Founder, Visara Vice Chairman of the Board, NovaBridge Carlos Quezada-Ruiz, MD, FASRS Chairman, ”